New Covenant Trust Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$680K Buy
2,600
+324
+14% +$83.1K 0.47% 36
2026
Q2
$573K Buy
2,276
+189
+9% +$40.7K 0.43% 41
2026
Q1
$454K Buy
2,087
+484
+30% +$107K 0.41% 40
2025
Q4
$368K Buy
1,603
+19
+1% +$4.33K 0.33% 45
2025
Q3
$367K Sell
1,584
-17
-1% -$3.46K 0.34% 45
2025
Q2
$292K Sell
1,601
-9
-0.6% -$1.67K 0.26% 56
2025
Q1
$331K Sell
1,610
-122
-7% -$23.7K 0.35% 50
2024
Q4
$305K Sell
1,732
-70
-4% -$12.9K 0.3% 52
2024
Q3
$351K Sell
1,802
-16
-0.9% -$2.99K 0.34% 46
2024
Q2
$313K Sell
1,818
-110
-6% -$18.2K 0.36% 46
2024
Q1
$351K Buy
+1,928
New +$332K 0.35% 40

Other funds holding ABBV

New Covenant Trust Company's ABBV Position: Q3 2026 in Review

New Covenant Trust Company increased its AbbVie (ABBV) stake by 14% in Q3 2026, buying an estimated $83.1K and bringing the position to 2,600 shares worth $680K. The position accounts for 0.47% of the portfolio, ranked #36.

New Covenant Trust Company first reported a position in ABBV in Q1 2024 and has held it in 11 quarters since. 246 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • New Covenant Trust Company held 2,600 shares of AbbVie worth $680K as of Q3 2026.
  • New Covenant Trust Company bought 324 AbbVie shares in Q3 2026, an estimated $83.1K.
  • AbbVie made up 0.47% of New Covenant Trust Company's portfolio in Q3 2026, its #36 holding.
  • New Covenant Trust Company first reported a position in AbbVie in Q1 2024 and has held it in 11 quarters since.
  • 246 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on New Covenant Trust Company's 13F filing for Q3 2026, filed 8 Oct 2026.